Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x100px
Collaboration › Details

Exscientia–Leucadia: investor conference, 202211 supply service Exscientia participates in Jefferies 2022 London Healthcare Conference


Period Period 2022-11-16
Region Region London, Greater London
  Country United Kingdom (GB)
Organisations Partner, 1st Exscientia plc (Nasdaq: EXAI)
  Group Exscientia (Group)
  Partner, 2nd Jefferies International Ltd.
  Group Leucadia (Group)
Products Product Jefferies 2022 London Healthcare Conference
  Product 2 AI-based drug discovery / AI-based drug development

Exscientia plc. (11/1/22). "Press Release: Exscientia to Present at Upcoming Investor Conferences in November". Oxford.

Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in November:

> BofA Securities 2022 A.I. and Disruptive Tech Conference. Fireside chat (AI in Drug Discovery) on Wednesday, November 9, 2022, at 12:40 p.m. EST (5:40 p.m. GMT)

> 2022 Jefferies London Healthcare Conference. Management will participate in investor meetings on Wednesday, November 16, 2022, in London, United Kingdom

> 5th Annual Evercore ISI HealthCONx Conference. Fireside chat onTuesday, November 29, 2022, at8:50 a.m. EST (1:50 p.m. GMT)

Live webcasts of the fireside chats will be available on the Company’s website, under the “Investors & Media” section at Archived replays of the webcasts will be available for approximately 30 days following the presentation.

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.

Exscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).

Visit us at or follow us on Twitter @exscientiaAI.

Sara Sherman


Record changed: 2022-11-08


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Exscientia (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Berlin Partner Top News Bayer Aignostics Collaboration 650x300px

» top